ChiCTR1800018900: A Phase I Clinical Trial of BAT4306F (for injection) on Safety, Tolerability and Pharmacokinetics for Patients with CD20-positive, B-cell non-Hodgkin's lymphoma |
|
|
| Not yet recruiting | 1 | 24 | | BAT4306F Injection: 100mg/4ml, BAT4306F 100mg/4mL, IV ;BAT4306F Injection 100mg/4ml, BAT4306F 100mg/4mL, IV ;BAT4306F Injection 100mg/4ml, BAT4306F 100mg/4mL, IV ;BAT4306F Injection 100mg/4ml, BAT4306F 100mg/4mL, IV | Beijing Cancer Hospital; Bio-thera Solutions, Ltd., Self-raised funds | Relapse/Refractory CD20+ B Cell Non-hodgkin's Lymphoma | | | | |
